Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Andrew Xiuxuan Zhu, Ph.D., M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Luo C, Liang J, Sharabi K, Hatting M, Perry EA, Tavares CDJ, Goyal L, Srivastava A, Bilodeau M, Zhu AX, Sicinski P, Puigserver P. Obesity/Type 2 Diabetes-Associated Liver Tumors Are Sensitive to Cyclin D1 Deficiency. Cancer Res. 2020 Jun 30. PMID: 32606000.
    Citations:    
  2. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020 05 14; 382(20):1894-1905. PMID: 32402160.
    Citations:    
  3. Parikh AR, Mojtahed A, Schneider JL, Kanter K, Van Seventer EE, Fetter IJ, Thabet A, Fish MG, Teshome B, Fosbenner K, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Ryan DP, Giantonio B, Goyal L, Nipp RD, Roeland E, Weekes CD, Wo JY, Zhu AX, Dias-Santagata D, Iafrate AJ, Lennerz JK, Hong TS, Siravegna G, Horick N, Clark JW, Corcoran RB. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clin Cancer Res. 2020 Apr 15; 26(8):1877-1885. PMID: 31941831.
    Citations:    
  4. Bitterman DS, Edgington SK, Kilcoyne A, Kim DW, Eyler CE, Qadan M, Ferrone CR, Tanabe KK, Goyal L, Zhu AX, Wo JY, Hong TS. Palliative External Beam Radiation Therapy for Hepatocellular Carcinoma With Right Atrial Tumor Thrombus. Pract Radiat Oncol. 2020 May - Jun; 10(3):e183-e187. PMID: 31931178.
    Citations:    
  5. Smart AC, Goyal L, Horick N, Petkovska N, Zhu AX, Ferrone CR, Tanabe KK, Allen JN, Drapek LC, Qadan M, Murphy JE, Eyler CE, Ryan DP, Hong TS, Wo JY. Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2020 Apr; 27(4):1122-1129. PMID: 31873931.
    Citations:    
  6. Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, Van Seventer EE, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, Danysh BP, de la Cruz FF, Fetter IJ, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Giantonio B, Murphy JE, Nipp RD, Roeland E, Ryan DP, Weekes CD, Kwak EL, Faris JE, Wo JY, Aguet F, Dey-Guha I, Hazar-Rethinam M, Dias-Santagata D, Ting DT, Zhu AX, Hong TS, Golub TR, Iafrate AJ, Adalsteinsson VA, Bardelli A, Parida L, Juric D, Getz G, Corcoran RB. Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019 Dec; 25(12):1949. PMID: 31745334.
    Citations:    
  7. Ferrone C, Goyal L, Qadan M, Gervais D, Sahani DV, Zhu AX, Hong TS, Blaszkowsky LS, Tanabe KK, Vangel M, Amorim BJ, Wo JY, Mahmood U, Pandharipande PV, Catana C, Duenas VP, Collazo YQ, Canamaque LG, Domachevsky L, Bernstine HH, Groshar D, Shih TT, Li Y, Herrmann K, Umutlu L, Rosen BR, Catalano OA. Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2020 Jul; 47(8):1871-1884. PMID: 31705172.
    Citations:    
  8. Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology. 2020 Apr; 71(4):1247-1261. PMID: 31378984.
    Citations:    
  9. Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, Van Seventer EE, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, Danysh BP, de la Cruz FF, Fetter IJ, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Giantonio B, Murphy JE, Nipp RD, Roeland E, Ryan DP, Weekes CD, Kwak EL, Faris JE, Wo JY, Aguet F, Dey-Guha I, Hazar-Rethinam M, Dias-Santagata D, Ting DT, Zhu AX, Hong TS, Golub TR, Iafrate AJ, Adalsteinsson VA, Bardelli A, Parida L, Juric D, Getz G, Corcoran RB. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019 09; 25(9):1415-1421. PMID: 31501609.
    Citations:    
  10. Brackett DG, Neyaz A, Arora K, Masia R, Mattia A, Zukerberg L, Misdraji J, Goyal L, Zhu AX, Ferrone CR, Yilmaz OH, Deshpande V. Cholangiolar pattern and albumin in situ hybridisation enable a diagnosis of intrahepatic cholangiocarcinoma. J Clin Pathol. 2020 Jan; 73(1):23-29. PMID: 31422372.
    Citations:    
  11. Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jul 01; 5(7):1020-1027. PMID: 31145418.
    Citations:    
  12. Bitterman DS, Sanford NN, Niemierko A, Mahal BA, Qadan M, Ganguli S, Blaszkowsky LS, Zhu AX, Hong TS, Devlin PM, Goyal L, Wo JY. Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-adjusted Analysis. Am J Clin Oncol. 2019 07; 42(7):564-572. PMID: 31166209.
    Citations:    
  13. Goyal L, Qadan M, Zhu AX. Another Treatment Option for Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis in China. JAMA Oncol. 2019 07 01; 5(7):938-939. PMID: 31070694.
    Citations:    
  14. Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019 08; 9(8):1064-1079. PMID: 31109923.
    Citations:    
  15. Franses JW, Hong TS, Zhu AX. Nivolumab with gemcitabine plus cisplatin for biliary cancers: as easy as ABC? Lancet Gastroenterol Hepatol. 2019 08; 4(8):575-577. PMID: 31109809.
    Citations:    
  16. Zhu AX, Finn RS, Galle PR, Llovet JM, Kudo M. Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of a-fetoprotein. Lancet Oncol. 2019 04; 20(4):e191. PMID: 30942178.
    Citations:    
  17. Franses JW, Zhu AX. Has PD-1 MET Its Match in Hepatocellular Carcinoma? Gastroenterology. 2019 05; 156(6):1563-1565. PMID: 30926349.
    Citations:    
  18. Lee GC, Ferrone CR, Tanabe KK, Lillemoe KD, Blaszkowsky LS, Zhu AX, Hong TS, Qadan M. Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resection. Am J Surg. 2019 11; 218(5):959-966. PMID: 30871788.
    Citations:    
  19. Costentin CE, Bababekov YJ, Zhu AX, Yeh H. Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceased-Donor Liver Transplantation? Hepatology. 2019 03; 69(3):1324-1336. PMID: 30229978.
    Citations:    Fields:    
  20. Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, Allen JN, Blaszkowsky LS, Ryan DP, Ferrone CR, Tanabe KK, Qadan M, Crane CH, Koay EJ, Eyler C, DeLaney TF, Zhu AX, Wo JY, Grassberger C, Hong TS. Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):64-72. PMID: 30684667.
    Citations:    Fields:    
  21. Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased a-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 02; 20(2):282-296. PMID: 30665869.
    Citations:    Fields:    
  22. Hong TS, Grassberger C, Yeap BY, Jiang W, Wo JY, Goyal L, Clark JW, Crane CH, Koay EJ, Dima S, Eyler CE, Popescu I, DeLaney TF, Zhu AX, Duda DG. Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. NPJ Precis Oncol. 2018; 2:22. PMID: 30374460.
    Citations:    
  23. Zhu AX, Aloia TA. Current status and evolving treatment for primary liver cancers. Chin Clin Oncol. 2018 Oct; 7(5):47. PMID: 30395715.
    Citations:    Fields:    
  24. Keane FK, Zhu AX, Hong TS. Radiotherapy for Biliary Tract Cancers. Semin Radiat Oncol. 2018 10; 28(4):342-350. PMID: 30309644.
    Citations:    Fields:    Translation:Humans
  25. Keane FK, Hong TS, Zhu AX. Evolving Systemic Therapy in Hepatocellular Carcinoma: Current Management and Opportunities for Integration With Radiotherapy. Semin Radiat Oncol. 2018 10; 28(4):332-341. PMID: 30309643.
    Citations:    Fields:    Translation:HumansAnimals
  26. Bhan I, Mosesso K, Goyal L, Philipp J, Kalinich M, Franses JW, Choz M, Oklu R, Toner M, Maheswaran S, Haber DA, Zhu AX, Chung RT, Aryee M, Ting DT. Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies From Patients With Liver Disease. Gastroenterology. 2018 12; 155(6):2016-2018.e11. PMID: 30218669.
    Citations:    Fields:    Translation:HumansCells
  27. Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2019 01 01; 25(1):80-89. PMID: 30190369.
    Citations:    Fields:    
  28. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018 08; 68(2):723-750. PMID: 29624699.
    Citations: 5     Fields:    Translation:Humans
  29. Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Faris JE, Zhu AX, Goyal L, Lillemoe KD, DeLaney TF, Fernández-Del Castillo C, Ferrone CR, Hong TS. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018 07 01; 4(7):963-969. PMID: 29800971.
    Citations:    Fields:    
  30. Wo JY, Niemierko A, Ryan DP, Blaszkowsky LS, Clark JW, Kwak EL, Lillemoe KD, Drapek LN, Zhu AX, Allen JN, Faris JE, Murphy JE, Nipp R, Fernandez-Del Castillo C, Ferrone CR, Hong TS. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. Am J Clin Oncol. 2018 07; 41(7):656-661. PMID: 28134673.
    Citations: 2     Fields:    
  31. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018 07; 19(7):940-952. PMID: 29875066.
    Citations: 9     Fields:    
  32. Wehrenberg-Klee E, Goyal L, Dugan M, Zhu AX, Ganguli S. Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2018 Nov; 41(11):1799-1802. PMID: 29845347.
    Citations:    Fields:    Translation:Humans
  33. Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Kudo M, Pfiffer T, Hatano E, Chung HC, Kopeckova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Hsu Y, Abada PB, Zhu AX. Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. Br J Cancer. 2018 07; 119(1):19-26. PMID: 29808014.
    Citations:    Fields:    
  34. Kamran SC, Clark JW, Zheng H, Borger DR, Blaszkowsky LS, Allen JN, Kwak EL, Wo JY, Parikh AR, Nipp RD, Murphy JE, Goyal L, Zhu AX, Iafrate AJ, Corcoran RB, Ryan DP, Hong TS. Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Med. 2018 May 17. PMID: 29771009.
    Citations: 1     Fields:    
  35. Farsad K, Costentin CE, Zhu AX. Hepatocellular Carcinoma With Portal Venous Invasion: Radiating New Hope? JAMA Oncol. 2018 05 01; 4(5):669-670. PMID: 29543953.
    Citations:    Fields:    
  36. McDuff SGR, Remillard KA, Zheng H, Raldow AC, Wo JY, Eyler CE, Drapek LC, Goyal L, Blaszkowsky LS, Clark JW, Allen JN, Parikh AR, Ryan DP, Ferrone CR, Tanabe KK, Wolfgang JA, Zhu AX, Hong TS. Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Pract Radiat Oncol. 2018 Nov - Dec; 8(6):414-421. PMID: 29937235.
    Citations:    Fields:    Translation:Humans
  37. Grassberger C, Hong TS, Hato T, Yeap BY, Wo JY, Tracy M, Bortfeld T, Wolfgang JA, Eyler CE, Goyal L, Clark JW, Crane CH, Koay EJ, Cobbold M, DeLaney TF, Jain RK, Zhu AX, Duda DG. Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1222-1225. PMID: 29859792.
    Citations:    Fields:    
  38. Weekes CD, Clark JW, Zhu AX. Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target? Lancet Oncol. 2018 05; 19(5):591-592. PMID: 29625880.
    Citations: 1     Fields:    
  39. Aoki S, Cobbold M, Zhu AX, Duda DG. Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage? Hepatology. 2018 03; 67(3):826-828. PMID: 29077214.
    Citations:    Fields:    Translation:Humans
  40. Finn RS, Zhu AX, Farah W, Almasri J, Zaiem F, Prokop LJ, Murad MH, Mohammed K. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis. Hepatology. 2018 01; 67(1):422-435. PMID: 28881497.
    Citations: 12     Fields:    Translation:Humans
  41. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 01; 67(1):358-380. PMID: 28130846.
    Citations: 58     Fields:    Translation:Humans
  42. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 01 20; 36(3):276-282. PMID: 29182496.
    Citations: 7     Fields:    
  43. Costentin CE, Ferrone CR, Arellano RS, Ganguli S, Hong TS, Zhu AX. Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy. Liver Cancer. 2017 Nov; 6(4):360-374. PMID: 29234639.
    Citations: 2     
  44. Pretz JL, Blake MA, Killoran JH, Mamon HJ, Wo JY, Zhu AX, Hong TS. Pilot study on the impact of F18-labeled thymidine PET/CT on gross tumor volume identification and definition for pancreatic cancer. Pract Radiat Oncol. 2018 May - Jun; 8(3):179-184. PMID: 29042120.
    Citations:    Fields:    Translation:Humans
  45. Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Tanguturi S, Goyal L, Murphy JE, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Tanabe KK, Ferrone CR, Ryan DP, Iafrate AJ, DeLaney TF, Zhu AX. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. J Natl Cancer Inst. 2017 09 01; 109(9). PMID: 28954285.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  46. Kambadakone A, Baliyan V, Zhu AX. Functional Imaging and Assessment of Antitumor Activity in Systemic Therapy for Hepatocellular Carcinoma. Semin Liver Dis. 2017 08; 37(3):259-274. PMID: 28847036.
    Citations:    Fields:    Translation:HumansAnimals
  47. Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov. 2017 09; 7(9):943-962. PMID: 28818953.
    Citations: 4     Fields:    Translation:HumansAnimals
  48. Zhu AX. Recent developments in systemic therapy for hepatocellular carcinoma. Clin Adv Hematol Oncol. 2017 Aug; 15 Suppl 9(8):7-13. PMID: 29036037.
    Citations:    Fields:    Translation:Humans
  49. El-Serag HB, Zhu AX, Johnson MS. The treatment path in hepatocellular carcinoma. Clin Adv Hematol Oncol. 2017 Aug; 15 Suppl 9(8):1-20. PMID: 29036035.
    Citations:    Fields:    Translation:Humans
  50. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep. 2017 06 27; 19(13):2878-2880. PMID: 28658632.
    Citations: 10     Fields:    
  51. Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. Eur J Cancer. 2017 08; 81:17-25. PMID: 28591675.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  52. Goyal L, Arkenau HT, Tran B, Soria JC, Bahleda R, Mak G, Zhu A, Javle M, Hiroshi H, Benedetti F, Huang J, Winkler R, Meric-Bernstam F. Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma. Ann Oncol. 2017 Jun; 28 Suppl 3:iii145. PMID: 32135780.
    Citations:    
  53. Parikh A, Goyal L, Hazar-Rethinam M, Siravegna G, Blaszkowsky L, Russo M, Van Seventer E, Nadres B, Shahzade H, Clark J, Allen J, John IA, Ryan DP, Murphy J, Bardelli A, Zhu A, Hong T, Corcoran R. Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients. Ann Oncol. 2017 Jun; 28 Suppl 3:iii137. PMID: 32135760.
    Citations:    
  54. Reyes S, Horick N, Clark J, Murphy J, Blaszkowsky L, Allen J, Ryan DP, Hong T, Wo J, Nipp R, Parikh A, Faris J, Kwak E, Galway A, Knowles M, Oklu R, John IA, Lennerz J, Finkelstein D, Borger D, Zhu A, Goyal L. Frequency and impact of tumor genotyping in clinical practice of patients with advanced biliary tract cancers (ABTCs). Ann Oncol. 2017 Jun; 28 Suppl 3:iii145-iii146. PMID: 32135779.
    Citations:    
  55. Benson AB, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017 05; 15(5):563-573. PMID: 28476736.
    Citations: 15     Fields:    Translation:Humans
  56. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep. 2017 03 14; 18(11):2780-2794. PMID: 28297679.
    Citations: 20     Fields:    Translation:HumansCells
  57. Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, Jeng KS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, Dima S, Popescu I, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, Duda DG. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Sci Rep. 2017 03 09; 7:44123. PMID: 28276530.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  58. Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer. 2017 06 01; 123(11):1979-1988. PMID: 28192597.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  59. Tanguturi SK, Niemierko A, Wo JY, Nguyen KN, Prichard H, Zhu AX, Wolfgang JA, Hong TS. Gallbladder toxicity and high-dose ablative-intent radiation for liver tumors: Should we constrain the dose? Pract Radiat Oncol. 2017 Sep - Oct; 7(5):e323-e329. PMID: 28341320.
    Citations:    Fields:    Translation:HumansPHPublic Health
  60. Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, Weissinger F, Brandi G, Barone CA, Okusaka T, Wada Y, Park JO, Ryoo BY, Cho JY, Chung HC, Li CP, Yen CJ, Lee KD, Chang SC, Yang L, Abada PB, Chau I. Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. JAMA Oncol. 2017 Feb 01; 3(2):235-243. PMID: 27657674.
    Citations: 10     Fields:    
  61. Kalinich M, Bhan I, Kwan TT, Miyamoto DT, Javaid S, LiCausi JA, Milner JD, Hong X, Goyal L, Sil S, Choz M, Ho U, Kapur R, Muzikansky A, Zhang H, Weitz DA, Sequist LV, Ryan DP, Chung RT, Zhu AX, Isselbacher KJ, Ting DT, Toner M, Maheswaran S, Haber DA. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2017 01 31; 114(5):1123-1128. PMID: 28096363.
    Citations: 14     Fields:    Translation:HumansCells
  62. Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, Mussolin B, Reyes S, Henderson L, Sun JE, Van Seventer EE, Gurski JM, Baltschukat S, Schacher-Engstler B, Barys L, Stamm C, Furet P, Ryan DP, Stone JR, Iafrate AJ, Getz G, Porta DG, Tiedt R, Bardelli A, Juric D, Corcoran RB, Bardeesy N, Zhu AX. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 2017 03; 7(3):252-263. PMID: 28034880.
    Citations: 23     Fields:    Translation:Humans
  63. Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol. 2016 Dec; 7(6):819-827. PMID: 28078106.
    Citations: 2     
  64. Park JO, Ryoo BY, Yen CJ, Kudo M, Yang L, Abada PB, Cheng R, Orlando M, Zhu AX, Okusaka T. Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. Oncotarget. 2016 Nov 15; 7(46):75482-75491. PMID: 27776351.
    Citations: 3     Fields:    Translation:Humans
  65. Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016 Nov 15; 122(22):3430-3446. PMID: 27622302.
    Citations: 14     Fields:    
  66. Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol. 2017 Apr; 52(4):494-503. PMID: 27549242.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  67. Chong DQ, Zhu AX. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Oncotarget. 2016 Jul 19; 7(29):46750-46767. PMID: 27102149.
    Citations: 11     Fields:    Translation:Humans
  68. McCarthy CJ, Zhu AX, Alansari SA, Oklu R. Transarterial Chemoembolization in the Coming Era of Decreased Reimbursement for Readmissions. J Am Coll Radiol. 2016 Aug; 13(8):915-21. PMID: 27325468.
    Citations:    Fields:    Translation:Humans
  69. Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo JC, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, Jenkins RL, Rieger-Christ KM, Sullivan TB, Hezel AF, Liss AS, Mizukami Y, Goyal L, Ferrone CR, Zhu AX, Joung JK, Shokat KM, Benes CH, Bardeesy N. Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discov. 2016 07; 6(7):727-39. PMID: 27231123.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  70. Zhu AX, Kang YK, Rosmorduc O, Evans TR, Santoro A, Ross P, Gane E, Vogel A, Jeffers M, Meinhardt G, Peña CE. Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial. Clin Cancer Res. 2016 Oct 01; 22(19):4870-4879. PMID: 27220960.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  71. Keane FK, Wo JY, Zhu AX, Hong TS. Liver-Directed Radiotherapy for Hepatocellular Carcinoma. Liver Cancer. 2016 Jul; 5(3):198-209. PMID: 27493895.
    Citations: 7     
  72. Zhu AX, Chen D, He W, Kanai M, Voi M, Chen LT, Daniele B, Furuse J, Kang YK, Poon RT, Vogel A, Chiang DY. Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. J Hepatol. 2016 08; 65(2):296-304. PMID: 27130844.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  73. Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist. 2016 05; 21(5):594-9. PMID: 27000463.
    Citations: 26     Fields:    Translation:Humans
  74. Chapuy CI, Sahai I, Sharma R, Zhu AX, Kozyreva ON. Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm. Oncologist. 2016 Apr; 21(4):514-20. PMID: 26975868.
    Citations: 2     Fields:    Translation:Humans
  75. Deshpande V, Konstantinidis IT, Castillo CF, Hezel AF, Haigis KM, Ting DT, Bardeesy N, Goyal L, Zhu AX, Warshaw AL, Lillemoe KD, Ferrone CR. Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. J Gastrointest Surg. 2016 05; 20(5):953-9. PMID: 26956004.
    Citations: 2     Fields:    Translation:Humans
  76. Asvadi NH, Anvari A, Uppot RN, Thabet A, Zhu AX, Arellano RS. CT-Guided Percutaneous Microwave Ablation of Tumors in the Hepatic Dome: Assessment of Efficacy and Safety. J Vasc Interv Radiol. 2016 Apr; 27(4):496-502; quiz 503. PMID: 26922977.
    Citations: 2     Fields:    Translation:Humans
  77. Hato T, Zhu AX, Duda DG. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy. 2016; 8(3):299-313. PMID: 26865127.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  78. Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016 Feb 10; 34(5):460-8. PMID: 26668346.
    Citations: 34     Fields:    Translation:HumansCTClinical Trials
  79. Deipolyi AR, Zhu AX, Oklu R. Intratumoral Vascular Shunting: Biomarker of Clinical Outcome and Source of Circulating Tumor Cells? Am J Clin Oncol. 2015 Dec; 38(6):621-6. PMID: 25333732.
    Citations:    Fields:    Translation:HumansCells
  80. Ferrone CR, Ting DT, Shahid M, Konstantinidis IT, Sabbatino F, Goyal L, Rice-Stitt T, Mubeen A, Arora K, Bardeesy N, Miura J, Gamblin TC, Zhu AX, Borger D, Lillemoe KD, Rivera MN, Deshpande V. Erratum to: The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1609. PMID: 25786746.
    Citations:    Fields:    
  81. Ferrone CR, Ting DT, Shahid M, Konstantinidis IT, Sabbatino F, Goyal L, Rice-Stitt T, Mubeen A, Arora K, Bardeesey N, Miura J, Gamblin TC, Zhu AX, Borger D, Lillemoe KD, Rivera MN, Deshpande V. Erratum to: The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1604. PMID: 25575648.
    Citations: 1     Fields:    
  82. Sabbatino F, Villani V, Yearley JH, Deshpande V, Cai L, Konstantinidis IT, Moon C, Nota S, Wang Y, Al-Sukaini A, Zhu AX, Goyal L, Ting DT, Bardeesy N, Hong TS, Fernandez-del Castillo C, Tanabe KK, Lillemoe KD, Ferrone S, Ferrone CR. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res. 2016 Jan 15; 22(2):470-8. PMID: 26373575.
    Citations: 24     Fields:    Translation:HumansCells
  83. Lee SH, Hayano K, Zhu AX, Sahani DV, Yoshida H. Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic Monotherapy. PLoS One. 2015; 10(9):e0136725. PMID: 26366997.
    Citations: 3     Fields:    Translation:Humans
  84. Lee SH, Hayano K, Zhu AX, Sahani DV, Yoshida H. Advanced Hepatocellular Carcinoma: Perfusion Computed Tomography-Based Kinetic Parameter as a Prognostic Biomarker for Prediction of Patient Survival. J Comput Assist Tomogr. 2015 Sep-Oct; 39(5):687-96. PMID: 26222909.
    Citations:    Fields:    Translation:Humans
  85. Niska JR, Keane FK, Wolfgang JA, Hahn PF, Wo JY, Zhu AX, Hong TS. Impact of intravenous contrast enhancement phase on target definition for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC): Observations from patients enrolled on a prospective phase 2 trial. Pract Radiat Oncol. 2016 Jan-Feb; 6(1):e9-16. PMID: 26598907.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  86. Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Chong DQ, Deshpande V, Borger DR, Iafrate AJ, Bardeesy N, Zheng H, Zhu AX. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist. 2015 Sep; 20(9):1019-27. PMID: 26245674.
    Citations: 12     Fields:    Translation:Humans
  87. Hesketh RL, Zhu AX, Oklu R. Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care? Am J Clin Oncol. 2015 Aug; 38(4):431-6. PMID: 25238287.
    Citations: 1     Fields:    Translation:HumansCells
  88. Forsmark CE, Diniz AL, Zhu AX. Consensus conference on hilar cholangiocarcinoma. HPB (Oxford). 2015 Aug; 17(8):666-8. PMID: 26172133.
    Citations: 3     Fields:    Translation:Humans
  89. Lee SH, Hayano K, Zhu AX, Sahani DV, Yoshida H. Dynamic Contrast-Enhanced MRI Kinetic Parameters as Prognostic Biomarkers for Prediction of Survival of Patient with Advanced Hepatocellular Carcinoma: A Pilot Comparative Study. Acad Radiol. 2015 Nov; 22(11):1344-60. PMID: 26211553.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  90. Reiberger T, Chen Y, Ramjiawan RR, Hato T, Fan C, Samuel R, Roberge S, Huang P, Lauwers GY, Zhu AX, Bardeesy N, Jain RK, Duda DG. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Nat Protoc. 2015 Aug; 10(8):1264-74. PMID: 26203823.
    Citations: 8     Fields:    Translation:Animals
  91. Goyal L, Chong DQ, Duda DG, Zhu AX. Chemotherapy and antiangiogenics in biliary tract cancer. Lancet Oncol. 2015 Aug; 16(8):882-3. PMID: 26179202.
    Citations: 1     Fields:    Translation:Humans
  92. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015 Jul; 16(7):859-70. PMID: 26095784.
    Citations: 82     Fields:    Translation:HumansCTClinical Trials
  93. Keane FK, Tanguturi SK, Zhu AX, Dawson LA, Hong TS. Radiotherapy for liver tumors. Hepat Oncol. 2015 Apr; 2(2):133-146. PMID: 30190993.
    Citations: 1     
  94. Sahani DV, Hayano K, Galluzzo A, Zhu AX. Measuring treatment response to systemic therapy and predicting outcome in biliary tract cancer: comparing tumor size, volume, density, and metabolism. AJR Am J Roentgenol. 2015 Apr; 204(4):776-81. PMID: 25794066.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  95. Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology. 2015 May; 61(5):1591-602. PMID: 25529917.
    Citations: 57     Fields:    Translation:HumansAnimals
  96. Fitamant J, Kottakis F, Benhamouche S, Tian HS, Chuvin N, Parachoniak CA, Nagle JM, Perera RM, Lapouge M, Deshpande V, Zhu AX, Lai A, Min B, Hoshida Y, Avruch J, Sia D, Campreciós G, McClatchey AI, Llovet JM, Morrissey D, Raj L, Bardeesy N. YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. Cell Rep. 2015 Mar 17; 10(10):1692-1707. PMID: 25772357.
    Citations: 42     Fields:    
  97. Huynh H, Hao HX, Chan SL, Chen D, Ong R, Soo KC, Pochanard P, Yang D, Ruddy D, Liu M, Derti A, Balak MN, Palmer MR, Wang Y, Lee BH, Sellami D, Zhu AX, Schlegel R, Huang A. Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. Mol Cancer Ther. 2015 May; 14(5):1224-35. PMID: 25724664.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  98. Zhu AX. Future directions in the treatment of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015 Apr; 29(2):355-61. PMID: 25966434.
    Citations: 9     Fields:    Translation:Humans
  99. Deipolyi AR, Oklu R, Al-Ansari S, Zhu AX, Goyal L, Ganguli S. Safety and efficacy of 70-150 µm and 100-300 µm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2015 Apr; 26(4):516-22. PMID: 25704226.
    Citations: 7     Fields:    Translation:Humans
  100. Moy AP, Shahid M, Ferrone CR, Borger DR, Zhu AX, Ting D, Deshpande V. Microsatellite instability in gallbladder carcinoma. Virchows Arch. 2015 Apr; 466(4):393-402. PMID: 25680569.
    Citations: 6     Fields:    Translation:HumansCells
  101. Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernández-del Castillo C. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015 Jan; 261(1):12-7. PMID: 25599322.
    Citations: 65     Fields:    Translation:Humans
  102. Hesketh RL, Zhu AX, Oklu R. Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma? Diagn Interv Radiol. 2015 Jan-Feb; 21(1):78-84. PMID: 25430530.
    Citations: 4     Fields:    Translation:HumansCells
  103. Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M, Meinhardt G, Kang YK. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015 Feb 20; 33(6):559-66. PMID: 25547503.
    Citations: 92     Fields:    Translation:HumansCTClinical Trials
  104. Ferrone CR, Ting DT, Shahid M, Konstantinidis IT, Sabbatino F, Goyal L, Rice-Stitt T, Mubeen A, Arora K, Bardeesey N, Miura J, Gamblin TC, Zhu AX, Borger D, Lillemoe KD, Rivera MN, Deshpande V. The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. Ann Surg Oncol. 2016 Jan; 23(1):290-6. PMID: 25519926.
    Citations: 7     Fields:    Translation:Humans
  105. Sheth RA, Arellano RS, Uppot RN, Samir AE, Goyal L, Zhu AX, Gervais DA, Mahmood U. Prospective trial with optical molecular imaging for percutaneous interventions in focal hepatic lesions. Radiology. 2015 Mar; 274(3):917-26. PMID: 25302707.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  106. Hato T, Goyal L, Greten TF, Duda DG, Zhu AX. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology. 2014 Nov; 60(5):1776-82. PMID: 24912948.
    Citations: 44     Fields:    Translation:Humans
  107. Goyal L, Wadlow RC, Blaszkowsky LS, Wolpin BM, Abrams TA, McCleary NJ, Sheehan S, Sundaram E, Karol MD, Chen J, Zhu AX. A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Invest New Drugs. 2015 Feb; 33(1):128-37. PMID: 25248753.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  108. Benson AB, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, Schefter T, Sigurdson ER, Tian GG, Vauthey JN, Venook AP, Yen Y, Zhu AX, Hoffmann KG, McMillian NR, Sundar H. Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw. 2014 Aug; 12(8):1152-82. PMID: 25099447.
    Citations: 14     Fields:    Translation:Humans
  109. Deipolyi AR, Iafrate AJ, Zhu AX, Ergul EA, Ganguli S, Oklu R. High lung shunt fraction in colorectal liver tumors is associated with distant metastasis and decreased survival. J Vasc Interv Radiol. 2014 Oct; 25(10):1604-8. PMID: 25086965.
    Citations: 4     Fields:    Translation:HumansCells
  110. Tanguturi SK, Wo JY, Zhu AX, Dawson LA, Hong TS. Radiation therapy for liver tumors: ready for inclusion in guidelines? Oncologist. 2014 Aug; 19(8):868-79. PMID: 25001265.
    Citations: 10     Fields:    Translation:Humans
  111. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. 2014 Jul 02; 312(1):57-67. PMID: 25058218.
    Citations: 112     Fields:    Translation:HumansCTClinical Trials
  112. Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, Zhu AX, Hezel AF, Yen KE, Straley KS, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S, Bardeesy N. Mutant IDH inhibits HNF-4a to block hepatocyte differentiation and promote biliary cancer. Nature. 2014 Sep 04; 513(7516):110-4. PMID: 25043045.
    Citations: 83     Fields:    Translation:HumansAnimalsCells
  113. Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, Groeschl RT, Deshpande V, Lindberg JM, Ferrone C, Sempoux C, Yau T, Poon R, Popescu I, Bauer TW, Gamblin TC, Gigot JF, Anders RA, Pawlik TM. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014 Nov; 21(12):3827-34. PMID: 24889489.
    Citations: 29     Fields:    Translation:Humans
  114. Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-del Castillo C, Duda DG. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):830-8. PMID: 24867540.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  115. Hyder O, Marques H, Pulitano C, Marsh JW, Alexandrescu S, Bauer TW, Gamblin TC, Sotiropoulos GC, Paul A, Barroso E, Clary BM, Aldrighetti L, Ferrone CR, Zhu AX, Popescu I, Gigot JF, Mentha G, Feng S, Pawlik TM. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg. 2014 May; 149(5):432-8. PMID: 24599477.
    Citations: 40     Fields:    Translation:Humans
  116. Hayano K, Lee SH, Yoshida H, Zhu AX, Sahani DV. Fractal analysis of CT perfusion images for evaluation of antiangiogenic treatment and survival in hepatocellular carcinoma. Acad Radiol. 2014 May; 21(5):654-60. PMID: 24703479.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  117. Russo AL, Ryan DP, Borger DR, Wo JY, Szymonifka J, Liang WY, Kwak EL, Blaszkowsky LS, Clark JW, Allen JN, Zhu AX, Berger DL, Cusack JC, Mamon HJ, Haigis KM, Hong TS. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. J Gastrointest Cancer. 2014 Mar; 45(1):34-9. PMID: 24006244.
    Citations: 9     Fields:    Translation:Humans
  118. Hayano K, Yoshida H, Zhu AX, Sahani DV. Fractal analysis of contrast-enhanced CT images to predict survival of patients with hepatocellular carcinoma treated with sunitinib. Dig Dis Sci. 2014 Aug; 59(8):1996-2003. PMID: 24563237.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  119. Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology. 2014 Apr; 59(4):1435-47. PMID: 24242874.
    Citations: 38     Fields:    Translation:AnimalsCells
  120. Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer. 2014 May 15; 120(10):1482-90. PMID: 24500602.
    Citations: 19     Fields:    Translation:Humans
  121. Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, Allen JN, Blaszkowsky LS, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Bardeesy N, Straley KS, Agresta S, Schenkein DP, Ellisen LW, Ryan DP, Zhu AX. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1884-90. PMID: 24478380.
    Citations: 26     Fields:    Translation:Humans
  122. Wo JY, Dawson LA, Zhu AX, Hong TS. An emerging role for radiation therapy in the treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2014 Apr; 23(2):353-68. PMID: 24560114.
    Citations: 5     Fields:    Translation:Humans
  123. Zhu AX. Current status of hepatocellular carcinoma in the United States. Chin Clin Oncol. 2013 Dec; 2(4):45. PMID: 25841924.
    Citations: 1     Fields:    
  124. Goyal L, Supko JG, Berlin J, Blaszkowsky LS, Carpenter A, Heuman DM, Hilderbrand SL, Stuart KE, Cotler S, Senzer NN, Chan E, Berg CL, Clark JW, Hezel AF, Ryan DP, Zhu AX. Phase 1 study of N(1),N(11)-diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1305-14. PMID: 24121453.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  125. Hong TS, DeLaney TF, Mamon HJ, Willett CG, Yeap BY, Niemierko A, Wolfgang JA, Lu HM, Adams J, Weyman EA, Arellano RS, Blaszkowsky LS, Allen JN, Tanabe KK, Ryan DP, Zhu AX. A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):316-322. PMID: 25194100.
    Citations: 9     Fields:    Translation:Humans
  126. Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG, Stuart K. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res. 2013 Dec 01; 19(23):6614-23. PMID: 24088738.
    Citations: 35